AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04854720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage® CAPSULE
Description: Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions.
Study NCT04696276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
Study NCT04707677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium and ceramic dental Implants
Description: Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
Study NCT04707677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium and ceramic dental Implants
Description: Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
Study NCT02214927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 tablet
Study NCT02214927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 drinking solution
Study NCT05477979 — intervention group
Intervention type: OTHER
Intervention: Exposure: psychological stress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
Study NCT04437069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).
Study NCT04437069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Values Clarification Exercise
Description: The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
Study NCT00838318 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Audiotaped Phone Interview/Survey, 30 - 45 minutes.
Study NCT04648059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling will be performed to allow analyses of epigenetic markers
Study NCT00508586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
Study NCT01559025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin ( Galvus 50mg twice day) during one year
Study NCT04820699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation and muligan bent leg raise
Description: 6 week intervention
Study NCT04820699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muligan bent leg raise
Description: muligan bent leg raise
Study NCT00765518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: CRCs will be administered via direct injection into the heart muscle.
Study NCT00765518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
Study NCT02384746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular every 28 days
Study NCT02384746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
Study NCT03921125 — intervention group
Intervention type: DEVICE
Intervention: Massimo for Pleth variability index
Description: To assess fluid response
Study NCT04450082 — intervention group
Intervention type: PROCEDURE
Intervention: One anastomosis gastric bypass
Description: The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
Study NCT02251418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Study NCT02693028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lozenges
Description: The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study NCT02693028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study NCT02693028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsules
Description: The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study NCT02693028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study NCT02693028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic chewing gum
Description: The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Study NCT05088174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule
Description: Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule
Study NCT00708552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457
Description: investigational drug
Study NCT04171102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProFlor Hernia implant
Description: Inguinal hernia repair
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 mg/kg CR8020
Description: administered as a single 2-hour intravenous infusion
Study NCT01756950 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered as a single 2-hour intravenous infusion
Study NCT00708552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: comparator
Study NCT00708552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator
Study NCT02083432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 session of CBT performed by specially trained dentists
Description: A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
Study NCT02083432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5 session of CBT performed by specially trained dentists
Description: A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
Study NCT05596305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational psychiatry intervention
Description: educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
Study NCT02107209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Lung volume reduction
Description: Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
Study NCT02107209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic Lung volume reduction
Description: Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
Study NCT03076970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasmiditan 200 mg
Description: drug including single placebo tablet
Study NCT03076970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: drug including single placebo tablet
Study NCT03076970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: drug including single placebo tablet
Study NCT03076970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
Study NCT03076970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
Study NCT04581525 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT04581525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01990846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide 3
Study NCT01990846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Flufirvitide-3
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, low dose
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, low dose
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, middle dose
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, middle dose
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2307
Description: subcutaneous, twice daily, high dose
Study NCT00785408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous, twice daily, high dose
Study NCT01345630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc tablet 150 mg once daily for 96 weeks.
Study NCT01345630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir
Description: Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
Study NCT01345630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 800/100 mg
Description: darunavir/ritonavir 800/100 mg
Study NCT01345630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for emtricitabine/tenofovir
Description: placebo for emtricitabine/tenofovir
Study NCT01345630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for maraviroc
Description: placebo for maraviroc
Study NCT03940599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: step counter
Description: Fitbit
Study NCT03940599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weight scale
Description: BodyTrace weight scale
Study NCT03940599 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: step counter with screen covered
Description: Fitbit with screen covered
Study NCT03940599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: step counter with screen covered
Description: Fitbit with screen covered
Study NCT03664479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study NCT05399745 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive monitoring
Description: Neurocognitive tests and MRI of the brain
Study NCT04051268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: 1 dose of Investigational Product
Study NCT04051268 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PQed Typhoid Conjugate Vaccine
Description: 1 dose of Active Comparator
Study NCT04051268 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide Vaccine
Description: 1 dose of Active Comparator
Study NCT03568370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil
Description: Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
Study NCT00275028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00669578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: CC-4047: taken orally each day in a 28 day cycle.
Study NCT03734289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Coaching
Description: Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
Study NCT02921932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure, Resource 2.0 and Glucerna
Description: Preoperative nutritional supplement for undernourished patients
Study NCT02921932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training, Memory Card Game
Description: Preoperative memory card game
Study NCT03948750 — intervention group
Intervention type: PROCEDURE
Intervention: Aqueous humour sampling
Description: Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
Study NCT00915031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroCool
Description: Hypothermia Endorectal Device
Study NCT01236079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted referral & IVR
Description: includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 solution
Description: Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 suspension
Description: Aqueous suspension of GSK2798745 (>=0.5 mg)
Study NCT02921932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc
Description: Inspiratory muscle trainer protocol for strengthening respiratory muscles
Study NCT01561326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-affective barriers counseling
Description: Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
Study NCT01561326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-affective barriers counseling via brochure
Description: Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
Study NCT01561326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 capsule
Description: White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
Study NCT02847091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral administration, 50mg once daily
Study NCT02847091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
Study NCT02339532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC100
Description: 3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²
Study NCT02339532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV